publications

Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.

Rafii, M SZaman, SHanden, B L

Summary

Those with Down syndrome (DS) are predisposed to developing dementia and Alzheimer’s disease (AD). The NIH-funded Alzheimer's Biomarker Consortium Down Syndrome (ABC-DS) and the European Horizon 21 Consortium are working together to collect information about the natural history of AD and biomarkers used to assess cognitive decline in adults with DS. This work has provided key insights into AD biomarkers for those with DS and this paper takes a look at how that data can be integrated into clinical trials.

Abstract

The NIH-funded Alzheimer's Biomarker Consortium Down Syndrome (ABC-DS) and the European Horizon 21 Consortium are collecting critical new information on the natural history of Alzheimer's Disease (AD) biomarkers in adults with Down syndrome (DS), a population genetically predisposed to developing AD. These studies are also providing key insights into which biomarkers best represent clinically meaningful outcomes that are most feasible in clinical trials. This paper considers how these data can be integrated in clinical trials for individuals with DS. The Alzheimer's Clinical Trial Consortium - Down syndrome (ACTC-DS) is a platform that brings expert researchers from both networks together to conduct clinical trials for AD in DS across international sites while building on their expertise and experience.

Conditions

Alzheimer Disease